Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia

Overview

Journal P T

Specialty Pharmacology

Date 2018 Jun 14

PMID 29896031

Citations 8

Authors

Stepan Uhlyar

Jose A Rey

Affiliations

Soon will be listed here.

Abstract

Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.

Citing Articles

Severe Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Following the Initiation of Valbenazine for Tardive Dyskinesia: A Case Report.

Adelakun A, Choi C, Brensilver J Cureus. 2024; 16(4):e58493.

PMID: 38765393 PMC: 11101299. DOI: 10.7759/cureus.58493.

Structural mechanisms for VMAT2 inhibition by tetrabenazine.

Dalton M, Cheng M, Bahar I, Coleman J Elife. 2024; 12.

PMID: 38517752 PMC: 10959523. DOI: 10.7554/eLife.91973.

Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.

Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K Tremor Other Hyperkinet Mov (N Y). 2024; 14:13.

PMID: 38497033 PMC: 10941689. DOI: 10.5334/tohm.842.

Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report.

Alhamoud A, Yatimi A, Towheri S, Sharahili H, Hawas A Cureus. 2022; 14(11):e31492.

PMID: 36408307 PMC: 9667702. DOI: 10.7759/cureus.31492.

Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.

Jurcau A, Jurcau M Biomedicines. 2022; 10(8).

PMID: 36009443 PMC: 9405755. DOI: 10.3390/biomedicines10081895.

References

Correll C, Leucht S, Kane J . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161(3):414-25. DOI: 10.1176/appi.ajp.161.3.414. View

Woods S, Morgenstern H, Saksa J, Walsh B, Sullivan M, Money R . Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71(4):463-74. PMC: 3109728. DOI: 10.4088/JCP.07m03890yel. View

Hauser R, Factor S, Marder S, Knesevich M, Ramirez P, Jimenez R . KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017; 174(5):476-484. DOI: 10.1176/appi.ajp.2017.16091037. View

Grigoriadis D, Smith E, Hoare S, Madan A, Bozigian H . Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017; 361(3):454-461. DOI: 10.1124/jpet.116.239160. View

Khaykin E, Eaton W, Ford D, Anthony C, Daumit G . Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010; 61(8):830-4. PMC: 7245045. DOI: 10.1176/ps.2010.61.8.830. View

Muller T . Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015; 24(6):737-42. DOI: 10.1517/13543784.2015.1029573. View

Leung J, Breden E . Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011; 45(4):525-31. DOI: 10.1345/aph.1P312. View

Lane R, Glazer W, Hansen T, Berman W, Kramer S . Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985; 173(6):353-7. DOI: 10.1097/00005053-198506000-00005. View

OBrien C, Jimenez R, Hauser R, Factor S, Burke J, Mandri D . NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015; 30(12):1681-7. PMC: 5049616. DOI: 10.1002/mds.26330. View

10.

Chang F, Fung V . Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med. 2014; 7:317-28. PMC: 4207069. DOI: 10.2147/PGPM.S52806. View

11.

Bhidayasiri R, Fahn S, Weiner W, Gronseth G, Sullivan K, Zesiewicz T . Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5):463-9. DOI: 10.1212/WNL.0b013e31829d86b6. View

12.

Waln O, Jankovic J . An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013; 3. PMC: 3709416. DOI: 10.7916/D88P5Z71. View

13.

Woerner M, Correll C, Alvir J, Greenwald B, Delman H, Kane J . Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology. 2011; 36(8):1738-46. PMC: 3138649. DOI: 10.1038/npp.2011.55. View